Sigma Healthcare Ltd (AU:SIG)
ASX:SIG
Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Select Model
Select Model
Rating:62Neutral
Price Target:
AU$3.00
▲(9.89% Upside)
Action:ReiteratedDate:10/10/25
The overall score of 62 is primarily driven by a strong technical posture, with the stock trading above all key moving averages, suggesting a bullish trend. However, this positive momentum is significantly tempered by a high valuation, as indicated by a P/E ratio of 57.9, and a negligible dividend yield, which may concern value-oriented investors.
Positive Factors
Scale & Distribution Network
Sigma's national wholesale and logistics footprint and pharmacy support services provide durable scale advantages. A broad distribution network supports recurring volume, strengthens supplier and retailer relationships, and creates higher switching costs for customers, aiding long-term revenue resilience.
Negative Factors
Negative Free Cash Flow
Persistent negative free cash flow and absent operating cash flow reduce Sigma's ability to self-fund working capital, capex, or initiatives to improve margins. Over months this raises liquidity and refinancing risk, increasing dependence on external funding and constraining strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & Distribution Network
Sigma's national wholesale and logistics footprint and pharmacy support services provide durable scale advantages. A broad distribution network supports recurring volume, strengthens supplier and retailer relationships, and creates higher switching costs for customers, aiding long-term revenue resilience.
Read all positive factors
Sigma Healthcare Ltd (SIG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$31.35B
Dividend Yield0.44%
Average Volume (3M)20.32M
Price to Earnings (P/E)22.3
Beta (1Y)0.54
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.03
Shares Outstanding11,543,703,000
10 Day Avg. Volume14,412,873
30 Day Avg. Volume20,321,286
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)5.38
Price to Sales (P/S)0.92
P/FCF Ratio-13.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.19Price Target Upside16.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$10.78B
Sigma Healthcare Ltd Business Overview & Revenue Model
Company Description
Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale and distribution of pharmaceutical products primarily in Australia. It operates approximately 1,200 branded and independent pharmacy stores under the Amcal, Discoun...
How the Company Makes Money
Sigma Healthcare generates revenue primarily through the wholesale distribution of pharmaceutical products to pharmacies and healthcare providers. Its key revenue streams include sales of prescription and over-the-counter medications, as well as h...
Sigma Healthcare Ltd Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.51B | 4.89B | 3.32B | 3.66B | 3.45B | 3.40B |
| Gross Profit | 1.16B | 334.05M | 189.82M | 224.07M | 199.42M | 210.61M |
| EBITDA | 614.50M | 55.47M | 53.25M | 50.20M | 30.23M | 68.96M |
| Net Income | 362.26M | -13.84M | 4.51M | 1.81M | -7.24M | 43.53M |
Balance Sheet | ||||||
| Total Assets | 8.74B | 1.83B | 1.40B | 1.20B | 1.28B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 163.13M | 14.57M | 356.50M | 16.65M | 31.14M | 16.13M |
| Total Debt | 3.04B | 132.09M | 136.63M | 226.99M | 323.43M | 215.23M |
| Total Liabilities | 3.85B | 991.29M | 531.52M | 723.84M | 786.65M | 705.00M |
| Stockholders Equity | 4.90B | 837.86M | 870.77M | 475.92M | 487.19M | 513.67M |
Cash Flow | ||||||
| Free Cash Flow | 80.43M | -323.50M | 37.25M | 113.34M | -60.48M | -64.56M |
| Operating Cash Flow | 109.69M | -315.59M | 41.97M | 142.74M | -46.28M | -13.13M |
| Investing Cash Flow | 31.58M | -1.60M | 5.73M | -28.60M | -16.59M | 124.36M |
| Financing Cash Flow | -339.17M | -24.73M | 295.82M | -116.94M | 128.89M | -265.71M |
Sigma Healthcare Ltd Technical Analysis
Positive
2.73
Price Trends
2.87
Negative
2.89
Negative
2.91
Negative
Market Momentum
-0.05
Negative
49.66
Neutral
47.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SIG, the sentiment is Positive. The current price of 2.73 is above the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.87, and below the 200-day MA of 2.91, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.66 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SIG.
Sigma Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | AU$1.17B | 31.27 | 9.57% | ― | 15.60% | 58.74% | |
65 Neutral | AU$69.00B | 34.11 | 7.56% | 2.58% | 6.07% | 13.75% | |
62 Neutral | AU$31.35B | 22.26 | 12.63% | 0.44% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$314.51M | -4.18 | -4.47% | ― | 21.68% | 37.78% | |
43 Neutral | AU$194.99M | -4.23 | -23.02% | ― | 5.07% | 46.14% | |
43 Neutral | AU$19.73M | -2.29 | 4388.00% | ― | -47.30% | 82.53% |
* Healthcare Sector Average
AU:SIG
Sigma Healthcare Ltd
2.73
-0.13
-4.41%
AU:MYX
Mayne Pharma Group
2.40
-4.83
-66.80%
AU:CSL
CSL
142.17
-110.28
-43.68%
AU:NAN
Nanosonics Limited
3.86
-0.92
-19.25%
AU:PGC
Paragon Care Limited
0.19
-0.21
-52.50%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-19.05%
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare Announces A$0.02 Interim Dividend for Half‑Year to December 2025
Feb 26, 2026
Sigma Healthcare has declared an ordinary interim dividend of A$0.02 per fully paid share, relating to the six‑month period ending 31 December 2025. The dividend will trade ex‑dividend on 4 March 2026, with a record date of 5 March and...
Sigma Healthcare posts double-digit profit growth as Chemist Warehouse network expands
Feb 25, 2026
Sigma Healthcare reported robust first-half 2026 results, with revenue rising 14.9% to $5.5 billion, normalised EBIT up 18.7% to $582.9 million and normalised NPAT up 19.2% to $392.0 million, underpinned by strong Chemist Warehouse store sales and...
Sigma Healthcare posts profit jump as Chemist Warehouse merger reshapes reporting
Feb 25, 2026
Sigma Healthcare, now reporting as a merged group with Chemist Warehouse, has aligned its financial year with Chemist Warehouse’s 30 June year-end following ASIC relief and corresponding ASX confirmations. The reverse acquisition accounting ...
Sigma Healthcare Issues 2.4 Million Unquoted Performance Rights Under Employee Incentive Scheme
Jan 15, 2026
Sigma Healthcare has notified the market of the issue of 2,403,962 unquoted performance rights under its employee incentive scheme, effective 9 January 2026. The new grants, which are not intended to be quoted on the ASX, form part of Sigma’...
Sigma Healthcare Grants Additional Performance Rights to Director Mario Verrocchi
Jan 15, 2026
Sigma Healthcare has disclosed a change in the interests of director Mario Verrocchi, who has been granted 314,021 rights to acquire fully paid ordinary shares under the company’s 2025 Long Term Incentive Plan, approved at its 2025 annual ge...
Sigma Healthcare Grants Long-Term Incentive Rights to Director Danielle Di Pilla
Jan 15, 2026
Sigma Healthcare has disclosed a change in director Danielle Di Pilla’s interests following the grant of 141,591 performance rights under the company’s 2025 Long Term Incentive Plan. The rights, issued for nil consideration as part of ...
Sigma Healthcare Grants Additional Long-Term Incentive Rights to CEO Vikesh Ramsunder
Jan 15, 2026
Sigma Healthcare has disclosed a change in the equity interests of its director and chief executive, Vikesh Ramsunder, following the allocation of new performance rights under its long-term incentive framework. The grant, made for nil consideratio...
Sigma Healthcare Sets Date for FY26 Half-Year Results and Investor Webcast
Jan 13, 2026
Sigma Healthcare has advised that it will publish its FY26 half-year financial results for the period ending 31 December 2025 to the ASX on the morning of Thursday, 26 February 2026. The company will follow the release with an investor webcast pre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.